IRIDEX - IRIX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IRIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRIX, but not buy additional shares or sell existing shares.
View IRIX analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month price objectives for IRIDEX's stock. Their IRIX share price forecasts range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next year. This suggests a possible upside of 38.9% from the stock's current price.
View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts.

IRIDEX's stock was trading at $6.11 on January 1st, 2022. Since then, IRIX shares have decreased by 64.6% and is now trading at $2.16.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our IRIX earnings forecast.

IRIDEX Co. (NASDAQ:IRIX) posted its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to analysts' expectations of $11.90 million. IRIDEX had a negative net margin of 15.50% and a negative trailing twelve-month return on equity of 43.06%. During the same period in the prior year, the company earned ($0.12) earnings per share.

IRIDEX updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $56.00 million-$58.00 million, compared to the consensus revenue estimate of $57.14 million.

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX's stock is owned by a variety of institutional and retail investors. Top institutional investors include Paragon Associates & Paragon Associates II Joint Venture (5.00%), Renaissance Technologies LLC (2.83%), Dimensional Fund Advisors LP (1.36%) and Perkins Capital Management Inc. (0.25%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends.

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRIX stock can currently be purchased for approximately $2.16.

IRIDEX (NASDAQ:IRIX) has a market capitalization of $34.54 million and generates $53.90 million in revenue each year. The medical equipment provider earns $-5,220,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

The company employs 119 workers across the globe.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710.